THA clinicals
Executive Summary
FDA said in a March 24 Talk Paper that the agency "will do everything possible to encourage Dr. Summers not to abandon any of his current patients." FDA has been investigating the researcher's study of THA in 35 patients with Alzheimer's disease, published in the Nov. 13, 1986 issue of The New England Journal of Medicine. "If patients are denied treatment by Dr. Summers, FDA has arranged with Warner-Lambert to set up a special protocol to provide continued treatment," the Talk Paper states.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.